Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial

This publication has 43 references indexed in Scilit:

• Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis
  Hepatology, 2016
• Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy
  Hepatology, 2015
• Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance
  Journal of Hepatology, 2014
• Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort
  Clinica Chimica Acta, 2013
• Bacterial DNA Translocation Is Associated With Systemic Circulatory Abnormalities and Intrahepatic Endothelial Dysfunction in Patients With Cirrhosis
  Hepatology, 2010
• Rifaximin Treatment in Hepatic Encephalopathy
  New England Journal of Medicine, 2010
• Neuropsychological characterization of hepatic encephalopathy
  Journal of Hepatology, 2001
• Utilization of Sialic Acid by Viridans Streptococci
  Journal of Dental Research, 1996
• Sialidase activity of the "Streptococcus milleri group" and other viridans group streptococci
  Journal of Clinical Microbiology, 1990
• Comparison of Lactulose and Neomycin in the Treatment of Chronic Portal-Systemic Encephalopathy
  Gastroenterology, 1977